期刊文献+

葡激酶突变体Y_1-Sak的体外变复性研究

Refolding of Recombinant Staphylokinase Variant Y_1-Sak from Escherichia coli
下载PDF
导出
摘要 具有低免疫原性的双功能葡激酶突变体Y1Sak(△15,S16K,K74A,E75A,R77A,K109R,F111D)在大肠杆菌中的表达产物为包涵体,必须进行体外变复性才能得到活性.详细研究了复性方式、pH、温度、复性的初始蛋白浓度和添加L精氨酸对Y1Sak的体外变复性的影响,发现复性温度和添加的L精氨酸对Y1Sak的复性有重要的影响.经过工艺优化后,Y1Sak的纯化活性回收率达到40%左右,蛋白比活性由20 kU/mg提高到53 kU/mg.用动态光散射分析发现,工艺优化后复性的高比活性Y1Sak的水合动力学半径与野生型葡激酶相近,分子基本处于单体状态. Recombinant staphylokinase variant Y1-Sak (△ 15, S16K, K74A, E75A, R77A, K109R, F111D) forms insoluble inclusion body when overexpressed in Escherichia coll. In order to acquire protein activity,in vitro denaturation and renaturation of Y1-Sak from inclusion bodies is required. The effects of various factors,including refolding methods, pH, temperature, the initial Y1-Sak concentration and L-arginine used as additive,on the refolding of Y1-Sak are studied. The results show that L-arginine plays a critical role in increasing refolding protein activity and the specific activity of Y1-Sak is greatly affected by refolding temperature. After process optimization, the specific activity of renatured Y1-Sak increased from 20 kU/mg to 53 kU/mg. Analysis of the products by dynamic light scattering shows the majority of Y1-Sak molecules with high specific activity exist as monomer and fewer Y1-Sak molecules aggregate to form dimmer and polymer.
出处 《河北师范大学学报(自然科学版)》 CAS 北大核心 2006年第4期459-463,共5页 Journal of Hebei Normal University:Natural Science
基金 国家863生物高技术研究发展计划项目(863-2001AA215291)
关键词 葡激酶突变体 复性 包涵体 staphylokinase refolding inclusion body
  • 相关文献

参考文献16

  • 1COLLEN D.Staphylokinase:A potent,uniquely fibrin-selective thrombolytic agent[J].Nat Med,1998,(4):279-284.
  • 2VANDERSCHUEREN S,BARRIOS L,KERDSINCHAI P,et al.A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction:The star trial group[J].Circulation,1995,92:2 044-2 049.
  • 3VANDERSCHUEREN S,DENS J,KERDSINCHAI P,et al.A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction[J].Am Heart J,1997,134(2Pt1):213-219.
  • 4VANDERSCHUEREN S,STOCKX L,WILMS G,et al.Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase[J].Circulation,1995,92:2 050-2 057.
  • 5DECLERCK P J,VANDERSCHUEREN S,BILLIET J,et al.Prevalence and induction of circulating antibodies against recombinant staphylokinase[J].Thromb Haemost,1994,71 (1):129-133.
  • 6COLLEN D,BERNAERTS R,DECLERCK P,et al.Recombinant staphylokinase variants with altered immunoreactivityⅠ:Construction and characterization[J].Circulation,1996,94 (2):197-206.
  • 7LAROCHE Y,HEYMANS S,CAPAERT S,et al.Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes[J].Blood,2000,96(4):1 425-1 432.
  • 8宋钢.葡激酶蛋白质工程研究[D].上海:复旦大学,2000.
  • 9HAUPTMANN J,GUHRS K H,HARTMANN M,et al.The fibrinolytic activity of staphylokinase mutants in the fibrin plate assay[J].Haemostasis,1995,25:272-276.
  • 10SAMBROOK J,FRITSCH E F,MANIATIS T.Detection and Analysis of Proteins Expressed from Cloned Genes[M].2nd ed.New York:Cold Spring Harbor Laboratory Press,1989.18.

二级参考文献3

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部